is easy to use "One Drop in the Morning and One Drop in the Evening"BEPREVE
(bepotastine besilate ophthalmic solution) 1.5% is a prescription anti-allergy eye drop that relieves itching associated with allergic conjunctivitis. It works on the two primary components of the allergic process that can lead to the development of allergy symptoms in the eye.1
Clinical studies show that BEPREVE provides complete relief in about 3 minutes in the majority of eyes with even severe itching of the eyes.2 Clinical studies have also shown that BEPREVE provides continuing relief for up to 8 hours post dosing.1
The safety of BEPREVE was evaluated in a clinical study of 861 patients over a period of 6 weeks.1 BEPREVE was shown to be comfortable in the eye,3 and can be used in patients as young as 2 years of age.1 IMPORTANT SAFETY INFORMATION: BEPREVE
is for topical ophthalmic use only. To minimize risk of contamination, do not touch the dropper tip to any surface. Keep the bottle closed when not in use. BEPREVE should not be used to treat contact lens–related irritation. Remove contact lenses prior to instillation of BEPREVE. The most common adverse reaction occurring in approximately 25% of patients was a mild taste following instillation. Other adverse reactions occurring in 2%-5% of patients were eye irritation, headache, and nasopharyngitis.ISTA Pharmaceuticals, Inc
. (NASDAQ: ISTA), is a rapidly growing pharmaceutical company, with the third largest branded prescription eye care business* in the United States and an emerging allergy drug franchise. The Company’s marketed products and development pipeline candidates are intended to address key segments of the $6.5 billion ophthalmic pharmaceutical market and the $2.5 billion nasal allergy market.ISTA
. currently markets four prescription products in the United States:
• BROMDAY™ (bromfenac ophthalmic solution) 0.09% for the treatment of inflammation and pain following cataract surgery;
• BEPREVE® (bepotastine besilate ophthalmic solution) 1.5%, recently launched for the treatment of ocular itching associated with signs and
symptoms of allergic conjunctivitis;
• ISTALOL ® (timolol maleate ophthalmic solution) 0.5% for the treatment of glaucoma;
• VITRASE ® (hyaluronidase injection) Ovine, 200USP Units/mL for use as a spreading agent.
BROMDAY, ISTALOL and VITRASE are each market leaders in their respective categories, with BROMDAY and ISTALOL continuing to grow faster than their market segments. To fuel the Company’s long-term growth, ISTA has several eye and allergy product candidates in various stages of development, including treatments for dry eye, ocular inflammation and pain and nasal allergies.
Headquartered in Irvine, California, ISTA Pharmaceuticals had 2010 revenues of $157 million. The Company has a staff of 326 employees, 167 of which are part of a scaled-up sales force calling on ophthalmologists, optometrists and allergists across the U.S. For additional information about ISTA Pharmaceuticals, please visit www.istavision.com
* IMS HEALTH data measuring sales prescribed by ophthalmologists
References: 1. BEPREVE [package insert]. Irvine, CA: ISTA Pharmaceuticals, Inc; 2010. 2. Clark JC, Williams JI, Gow JA, et al. Bepotastine besilate ophthalmic solution 1.5% rapidly eliminates ocular itching in more severely allergic subjects in the conjunctival allergen challenge model of allergic conjunctivitis. Poster presented at: Eastern Allergy Conference; May 6-9, 2010; Palm Beach, FL. 3. Data on file. ISTA Pharmaceuticals, Inc.